Pulmonary magnetic resonance-guided online adaptive radiotherapy of locally advanced non-small-cell lung cancer: the PUMA trial
暂无分享,去创建一个
C. Thieke | A. Kopp-Schneider | G. Landry | C. Belka | S. Corradini | J. Dinkel | D. Zips | D. Thorwarth | O. Sedlaczek | O. Jäkel | H. Schlemmer | J. Debus | J. Hörner-Rieber | C. Gillmann | C. Eze | S. Regnery | F. Seith | C. K. Renkamp | Chiara de Colle
[1] M. Alber,et al. Survival benefits for non-small cell lung cancer patients treated with adaptive radiotherapy. , 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[2] J. Debus,et al. Adaptive MR-Guided Stereotactic Radiotherapy is Beneficial for Ablative Treatment of Lung Tumors in High-Risk Locations , 2022, Frontiers in Oncology.
[3] Haihua Yang,et al. Adaptive intensity-modulated radiotherapy with simultaneous integrated boost for stage III non-small cell lung cancer: Is a routine adaptation beneficial? , 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[4] J. Debus,et al. Cone-Beam-CT Guided Adaptive Radiotherapy for Locally Advanced Non-small Cell Lung Cancer Enables Quality Assurance and Superior Sparing of Healthy Lung , 2020, Frontiers in Oncology.
[5] W. Ryder,et al. Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study , 2020, International journal of radiation oncology, biology, physics.
[6] D. Lynch,et al. Expanding Applications of Pulmonary MRI in the Clinical Evaluation of Lung Disorders: Fleischner Society Position Paper. , 2020, Radiology.
[7] C. Belka,et al. Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer , 2020, Radiation oncology.
[8] K. Kaira,et al. Pattern of Local Failure and its Risk Factors of Locally Advanced Non-small Cell Lung Cancer Treated With Concurrent Chemo-radiotherapy , 2020, AntiCancer Research.
[9] L. Kepka,et al. Accelerated hypofractionated radiotherapy with concurrent full dose chemotherapy for locally advanced non-small cell lung cancer: A phase I/II study. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[10] Sonja Adebahr,et al. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. , 2020, The Lancet. Oncology.
[11] S. Senan,et al. Clinical outcomes of stereotactic MR-guided adaptive radiation therapy for high-risk lung tumors. , 2020, International journal of radiation oncology, biology, physics.
[12] Suresh Senan,et al. Stereotactic MR-guided adaptive radiation therapy for peripheral lung tumors. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[13] Suresh Senan,et al. Role of On-Table Plan Adaptation in MR-Guided Ablative Radiation Therapy for Central Lung Tumors. , 2019, International journal of radiation oncology, biology, physics.
[14] Sebastian Klüter,et al. Technical design and concept of a 0.35 T MR-Linac , 2019, Clinical and translational radiation oncology.
[15] K. Frey,et al. Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[16] M. Barton,et al. MRI-Linear Accelerator Radiotherapy Systems. , 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).
[17] Parag J. Parikh,et al. Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial , 2018, Advances in radiation oncology.
[18] Marcel van Herk,et al. Magnetic Resonance Imaging-Guided Radiation Therapy: A Short Strengths, Weaknesses, Opportunities, and Threats Analysis. , 2018, International journal of radiation oncology, biology, physics.
[19] Arnaud Boyer,et al. Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. , 2018, Journal of thoracic disease.
[20] J P Cuijpers,et al. Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[21] Randall K Ten Haken,et al. Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer: A Phase 2 Clinical Trial , 2017, JAMA oncology.
[22] Sara Ramella,et al. Local Control and Toxicity of Adaptive Radiotherapy Using Weekly CT Imaging: Results from the LARTIA Trial in Stage III NSCLC , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[23] J. Bradley,et al. Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[24] Markus Alber,et al. Adaptive radiotherapy for advanced lung cancer ensures target coverage and decreases lung dose. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[25] P. Harari,et al. Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] Jinzhong Yang,et al. Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[27] J. Sonke,et al. Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[28] J. Aerts,et al. Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[29] R. Salgia,et al. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). , 2015, International journal of radiation oncology, biology, physics.
[30] W. Curran,et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.
[31] Jan-Jakob Sonke,et al. Intra thoracic anatomical changes in lung cancer patients during the course of radiotherapy. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[32] Benjamin Movsas,et al. Defining Local-Regional Control and Its Importance in Locally Advanced Non-small Cell Lung Carcinoma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[33] Philippe Giraud,et al. Respiratory Gating Techniques for Optimization of Lung Cancer Radiotherapy , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[34] M. Partridge,et al. Adaptive radiotherapy for locally advanced non-small-cell lung cancer does not underdose the microscopic disease and has the potential to increase tumor control. , 2011, International journal of radiation oncology, biology, physics.
[35] Benjamin Movsas,et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. , 2011, Journal of the National Cancer Institute.
[36] M. Ridder,et al. Toxicity report of a phase 1/2 dose‐escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy , 2009, Cancer.
[37] Hisao Asamura,et al. The IASLC Lung Cancer Staging Project: A Proposal for a New International Lymph Node Map in the Forthcoming Seventh Edition of the TNM Classification for Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[38] Matthias Guckenberger,et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. , 2009, International journal of radiation oncology, biology, physics.
[39] Wolfgang A Tomé,et al. Tumor volume changes on serial imaging with megavoltage CT for non-small-cell lung cancer during intensity-modulated radiotherapy: how reliable, consistent, and meaningful is the effect? , 2006, International journal of radiation oncology, biology, physics.
[40] Suresh Senan,et al. Benefit of respiration-gated stereotactic radiotherapy for stage I lung cancer: an analysis of 4DCT datasets. , 2005, International journal of radiation oncology, biology, physics.
[41] J. Galvin,et al. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Benjamin Movsas,et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. , 2012, International journal of radiation oncology, biology, physics.
[43] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[44] R Mackie,et al. A new approach to dose escalation in non-small-cell lung cancer. , 2001, International journal of radiation oncology, biology, physics.